

## SWIXX BIOPHARMA EARNS ECOVADIS SILVER MEDAL, RANKING AMONG THE TOP 15% GLOBALLY

**Baar, Switzerland, June 10<sup>th</sup>, 2026** – Swixx BioPharma is proud to announce that it has been awarded a Silver Medal by EcoVadis, placing the company among the top 90<sup>th</sup> percentile of all companies assessed globally within last 12 months.

This recognition represents an important milestone in the company's sustainability journey and reflects the collective effort of teams across the organization to integrate responsible business practices into everyday operations. Compared with 2024, Swixx BioPharma achieved a score that is twice as high, marking significant progress in the company's ESG performance.

### A Recognized Global Standard

EcoVadis is a globally recognized provider of business sustainability ratings, evaluating companies across four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement.

Achieving the Silver Medal confirms that Swixx BioPharma has established a strong foundation in sustainability and operates in alignment with international standards and best practices. This achievement builds on a clear and consistent path: the introduction of the Strategy Framework in 2024, the publication of the company's first ESG Report in 2025, and now, in 2026, the EcoVadis Silver Medal recognition.

### Driving Long-Term Value Through Sustainability and Responsibility


For Swixx BioPharma, sustainability is not a standalone initiative - it is an integral part of how the company creates long-term value, manages risks, and builds trust with stakeholders.

This recognition reflects the commitment of colleagues across our organization who work every day to integrate responsible business practices into how we serve patients, partners, employees, and communities.

### Looking Ahead

While celebrating this achievement, Swixx BioPharma remains focused on continuous improvement across environmental, social, ethical, and governance (ESG) dimensions.

The EcoVadis medal is valid for one year, during which the company will actively communicate its progress while continuing to strengthen its sustainability performance and prepare for future assessments.

 **Barbara Košir, NED and ESG Ambassador of Swixx Biopharma**, said: "Achieving a Silver Medal and ranking among the top 10% of companies assessed by EcoVadis within the past 12 months is a milestone that makes me incredibly proud. While the score itself is important, what truly represents is the collective effort, commitment, and collaboration of colleagues across our organization."



Over the past years, we have worked hard to embed sustainability into the way we operate and make decisions. This recognition confirms that we are moving in the right direction and that responsible business practices are becoming an increasingly integral part of our culture.

I would like to sincerely thank everyone who contributed to this achievement. Their expertise, dedication, and willingness to go the extra mile made this result possible. While we celebrate this important milestone today, we remain focused on continuously improving our environmental, social, ethical, and governance performance and creating lasting value for our stakeholders."

### About Swixx Biopharma

Swixx Biopharma is one of the largest commercialization platforms representing the portfolio of pharmaceutical companies in those markets in which they choose not to enter or decide to exit. Swixx Biopharma operates across multiple countries in Central and Eastern Europe, Greece, Eurasia and several CIS countries, the Middle East and Latin America. With a presence in 45+ countries and sales expected to reach €1.3 billion in 2026, Swixx is one of the fastest-growing independent biopharma commercialization platforms. Gathering outstanding rare disease, oncology-hematology, CNS, specialty and vaccines talent under one roof, Swixx Biopharma entered 2026 with more than 1,700 employees on board. For more information about Swixx, please visit: [www.swixxbiopharma.com](http://www.swixxbiopharma.com).



### Swixx Group media inquiries:

Vedrana Sokac Brataljenovic, Public Affairs Director  
[vedrana.sokac@swixxbiopharma.com](mailto:vedrana.sokac@swixxbiopharma.com), Tel: +385 1 425 6086

